Search Results - "Mason, Stefanie"

Significant Spirometric Transitions and Preserved Ratio Impaired Spirometry Among Ever Smokers by Wan, Emily S., Hokanson, John E., Regan, Elizabeth A., Young, Kendra A., Make, Barry J., DeMeo, Dawn L., Mason, Stefanie E., San Jose Estepar, Raul, Crapo, James D., Silverman, Edwin K.

“…Emerging data from longitudinal studies suggest that preserved ratio impaired spirometry (PRISm), defined by proportionate reductions in FEV1 and FVC, is a…”
Get full text

Relationship between Emphysema Progression at CT and Mortality in Ever-Smokers: Results from the COPDGene and ECLIPSE Cohorts by Ash, Samuel Y, San José Estépar, Raúl, Fain, Sean B, Tal-Singer, Ruth, Stockley, Robert A, Nordenmark, Lars H, Rennard, Stephen, Han, MeiLan K, Merrill, Debora, Humphries, Stephen M, Diaz, Alejandro A, Mason, Stefanie E, Rahaghi, Farbod N, Pistenmaa, Carrie L, Sciurba, Frank C, Vegas-Sánchez-Ferrero, Gonzalo, Lynch, David A, Washko, George R

“…Background The relationship between emphysema progression and long-term outcomes is unclear. Purpose To determine the relationship between emphysema…”
Get full text

Preoperative Brain Injury in Transposition of the Great Arteries Is Associated With Oxygenation and Time to Surgery, Not Balloon Atrial Septostomy by PETIT, Christopher J, ROME, Jonathan J, WERNOVSKY, Gil, MASON, Stefanie E, SHERA, David M, NICOLSON, Susan C, MONTENEGRO, Lisa M, TABBUTT, Sarah, ZIMMERMAN, Robert A, LICHT, Daniel J

“…Preoperative brain injury is an increasingly recognized phenomenon in neonates with complex congenital heart disease. Recently, reports have been published…”
Get full text

Quantitative Interstitial Abnormality Progression and Outcomes in the Genetic Epidemiology of COPD and Pittsburgh Lung Screening Study Cohorts by Choi, Bina, Adan, Najma, Doyle, Tracy J., San José Estépar, Ruben, Harmouche, Rola, Humphries, Stephen M., Moll, Matthew, Cho, Michael H., Putman, Rachel K., Hunninghake, Gary M., Kalhan, Ravi, Liu, Gabrielle Y., Diaz, Alejandro A., Mason, Stefanie E., Rahaghi, Farbod N., Pistenmaa, Carrie L., Enzer, Nicholas, Poynton, Clare, Sánchez-Ferrero, Gonzalo Vegas, Ross, James C., Lynch, David A., Martinez, Fernando J., Han, MeiLan K., Bowler, Russell P., Wilson, David O., Rosas, Ivan O., Washko, George R., San José Estépar, Raúl, Ash, Samuel Y.

“…The risk factors and clinical outcomes of quantitative interstitial abnormality progression over time have not been characterized. What are the associations of…”
Get full text

Distinguishing Smoking-Related Lung Disease Phenotypes Via Imaging and Molecular Features by Billatos, Ehab, Ash, Samuel Y., Duan, Fenghai, Xu, Ke, Romanoff, Justin, Marques, Helga, Moses, Elizabeth, Han, MeiLan K., Regan, Elizabeth A., Bowler, Russell P., Mason, Stefanie E., Doyle, Tracy J., San José Estépar, Rubén, Rosas, Ivan O., Ross, James C., Xiao, Xiaohui, Liu, Hanqiao, Liu, Gang, Sukumar, Gauthaman, Wilkerson, Matthew, Dalgard, Clifton, Stevenson, Christopher, Whitney, Duncan, Aberle, Denise, Spira, Avrum, San José Estépar, Raúl, Lenburg, Marc E., Washko, George R.

“…Chronic tobacco smoke exposure results in a broad range of lung pathologies including emphysema, airway disease and parenchymal fibrosis as well as a multitude…”
Get full text

Semi-quantitative visual assessment of chest radiography is associated with clinical outcomes in critically ill patients by Mason, Stefanie E, Dieffenbach, Paul B, Englert, Joshua A, Rogers, Angela A, Massaro, Anthony F, Fredenburgh, Laura E, Higuera, Angelica, Pinilla-Vera, Mayra, Vilas, Marta, San Jose Estepar, Raul, Washko, George R, Baron, Rebecca M, Ash, Samuel Y

“…Respiratory pathology is a major driver of mortality in the intensive care unit (ICU), even in the absence of a primary respiratory diagnosis. Prior work has…”
Get full text

Optical measurement of cerebral hemodynamics and oxygen metabolism in neonates with congenital heart defects by Durduran, Turgut, Zhou, Chao, Buckley, Erin M, Kim, Meeri N, Yu, Guoqiang, Choe, Regine, Gaynor, J. William, Spray, Thomas L, Durning, Suzanne M, Mason, Stefanie E, Montenegro, Lisa M, Nicolson, Susan C, Zimmerman, Robert A, Putt, Mary E, Wang, Jiongjiong, Greenberg, Joel H, Detre, John A, Yodh, Arjun G, Licht, Daniel J

“…We employ a hybrid diffuse correlation spectroscopy (DCS) and near-infrared spectroscopy (NIRS) monitor for neonates with congenital heart disease (n=33). The…”
Get full text

Cost-effectiveness microsimulation of catheter-directed thrombolysis in submassive pulmonary embolism using a right ventricular function model by Mason, Stefanie E., Zhu, Jinyi, Rahaghi, Farbod N., Washko, George R., Pandya, Ankur

“…Approximately 30–50% of hemodynamically stable patients presenting with acute pulmonary embolism (PE) have evidence of right ventricular (RV) dysfunction…”
Get full text

Seizures as a Presenting Symptom of Acute Arterial Ischemic Stroke in Childhood by Abend, Nicholas S., MD, Beslow, Lauren A., MD, Smith, Sabrina E., MD, PhD, Kessler, Sudha K., MD, Vossough, Arastoo, MD, PhD, Mason, Stefanie, BS, Agner, Shannon, MS, Licht, Daniel J., MD, Ichord, Rebecca N., MD

“…Objectives To define the incidence of seizures as a presenting symptom of acute arterial ischemic stroke (AIS) in children and to determine whether younger…”
Get full text

Arterial spin labeling perfusion MRI in pediatric arterial ischemic stroke: Initial experiences by Chen, Juan, Licht, Daniel J., Smith, Sabrina E., Agner, Shannon C., Mason, Stefanie, Wang, Sumei, Silvestre, David W., Detre, John A., Zimmerman, Robert A., Ichord, Rebecca N., Wang, Jiongjiong

“…Purpose To investigate the feasibility and utility of arterial spin labeling (ASL) perfusion MRI for characterizing alterations of cerebral blood flow (CBF) in…”
Get full text

O19: Integrated analyses of data from clinical trials of delandistrogene moxeparvovec gene therapy in DMD by O’Rourke, Erin, Proud, Crystal, Zaidman, Craig, Shieh, Perry B., McDonald, Craig, Day, John W., Mason, Stefanie, Guridi, Maitea, Han, Lixin, Yu, Lixi, Reid, Carol, Darton, Eddie, Wandel, Christoph, Richardson, James, Malhotra, Jyoti, Singh, Teji, Rodino-Klapac, Louise, Mendell, Jerry

Get full text

P314: Long-term safety and sustained functional benefit in patients with DMD 4 years post-treatment with delandistrogene moxeparvovec: A phase 1/2a study by O’Rourke, Erin, Mendell, Jerry R., Sahenk, Zarife, Lehman, Kelly J., Lowes, Linda P., Reash, Natalie F., Iammarino, Megan, Alfano, Lindsay, Lewis, Sarah, Church, Kathleen, Shell, Richard, Potter, Rachael A., Griffin, Danielle, Hogan, Mark J., Wang, Shufang, Mason, Stefanie, Darton, Eddie, Rodino-Klapac, Louise

Get full text

The implication of coronary artery malformations and congenital heart disease on cardiomyopathy by Mason, Stefanie E, Lipshultz, Steven E, Kaushal, Sunjay, Fisher, Stacy

“…Abstract Coronary and congenital heart malformations contribute to and overlap with clinical cardiomyopathy. As cellular mechanisms and gene associations are…”
Get full text

Long‐term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial by Mendell, Jerry R., Sahenk, Zarife, Lehman, Kelly J., Lowes, Linda P., Reash, Natalie F., Iammarino, Megan A., Alfano, Lindsay N., Lewis, Sarah, Church, Kathleen, Shell, Richard, Potter, Rachael A., Griffin, Danielle A., Hogan, Mark, Wang, Shufang, Mason, Stefanie, Darton, Eddie, Rodino‐Klapac, Louise R.

“…Introduction/Aims Delandistrogene moxeparvovec is indicated in the United States for the treatment of ambulatory pediatric patients aged 4 through 5 years with…”
Get full text

Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy by Mendell, Jerry R., Proud, Crystal, Zaidman, Craig M., Mason, Stefanie, Darton, Eddie, Wang, Shufang, Wandel, Christoph, Murphy, Alexander P., Mercuri, Eugenio, Muntoni, Francesco, McDonald, Craig M.

“…Delandistrogene moxeparvovec is a gene transfer therapy approved in the United States, United Arab Emirates, and Qatar for the treatment of ambulatory patients…”
Get full text

Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1‐Year Interim Results from Study SRP‐9001‐103 (ENDEAVOR) by Zaidman, Craig M., Proud, Crystal M., McDonald, Craig M., Lehman, Kelly J., Goedeker, Natalie L., Mason, Stefanie, Murphy, Alexander P., Guridi, Maitea, Wang, Shufang, Reid, Carol, Darton, Eddie, Wandel, Christoph, Lewis, Sarah, Malhotra, Jyoti, Griffin, Danielle A., Potter, Rachael A., Rodino‐Klapac, Louise R., Mendell, Jerry R.

“…Objective Delandistrogene moxeparvovec is approved in the USA for the treatment of ambulatory patients (4–5 years) with Duchenne muscular dystrophy. ENDEAVOR…”
Get full text

EMBARK, a Phase 3 Trial Evaluating Safety and Efficacy of Delandistrogene Moxeparvovec (SRP- 9001) in Duchenne Muscular Dystrophy (DMD): Study Design and Baseline Characteristics (P5-8.012) by Muntoni, Francesco, Mercuri, Eugenio, Schmidt, Ulrike Schara, Komaki, Hirofumi, Richardson, James, Singh, Tejdip, Guridi, Maitea, Mason, Stefanie, Murphy, Alex, Yu, Lixi, Reid, Carol, Darton, Eddie, Wandel, Christoph, Mendell, Jerry

“…Abstract only…”
Get full text

One-year Data from ENDEAVOR, a Phase 1b Trial of Delandistrogene Moxeparvovec (SRP-9001) in Patients with Duchenne Muscular Dystrophy (DMD) (S48.003) by Zaidman, Craig, Proud, Crystal, McDonald, Craig, Mason, Stefanie, Guridi, Maitea, Wang, Shufang, Reid, Carol, Darton, Eddie, Wandel, Christoph, Lewis, Sarah, Malhotra, Jyoti, Griffin, Danielle, Potter, Rachael, Rodino-Klapac, Louise, Mendell, Jerry

“…Abstract only…”
Get full text

Integrated Analyses of Data from Clinical Trials of Delandistrogene Moxeparvovec (SRP-9001) in Duchenne Muscular Dystrophy (DMD) (S48.006) by Proud, Crystal, Zaidman, Craig, Shieh, Perry, McDonald, Craig, Day, John, Mason, Stefanie, Guridi, Maitea, Han, Lixin, Yu, Lixi, Reid, Carol, Darton, Eddie, Wandel, Christoph, Richardson, James, Malhotra, Jyoti, Singh, Tejdip, Rodino-Klapac, Louise, Mendell, Jerry

“…Abstract only…”
Get full text

Long-term Safety and Efficacy in Patients with DMD 4 Years Post-Treatment with Delandistrogene Moxeparvovec (SRP-9001) in a Phase 1/2a Study (P3-8.006) by Mendell, Jerry, Sahenk, Zarife, Lehman, Kelly, Lowes, Linda, Reash, Natalie, Iammarino, Megan, Alfano, Lindsay, Lewis, Sarah, Church, Kathleen, Shell, Richard, Potter, Rachael, Griffin, Danielle, Hogan, Mark, Wang, Shufang, Mason, Stefanie, Darton, Eddie, Rodino-Klapac, Louise

“…Abstract only…”
Get full text